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Abstract 
Background: Malignant mesothelioma (MM) is a rare and fatal neoplasm. For diffuse malignant mesothelioma 
(DMM) patients that were not suitable for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, 
systemic chemotherapy is the main treatment. There are no convenient tumor markers to predict the efficacy of treat‑
ment and disease progression. This study aimed to evaluate serum CA125 level as a biochemical marker of response 
to therapy and prognosis in patients with DMM.
Methods: A retrospective study was performed in a single medical institution from April 2008 to April 2014. Overall 
survival (OS) and prognostic factors were assessed.
Results: Forty‑one patients were included with a median age of 53 years. The median OS of all patients was 
10 months. Patients with baseline CA125 > 280 U/ml had worse OS compared with the patients that baseline 
CA125 ≤ 280 U/ml. Baseline level of CA125, stage of disease, primary tumor location and systemic chemotherapy 
were independent prognostic factors associated with OS. In patients who received systemic chemotherapy, the 
decline in serum CA125 was associated with favorable OS and objective response according to modified Response 
Evaluation Criteria in Solid Tumors criteria.
Conclusions: The baseline level of serum CA125, accompanied with stage of disease, primary tumor location and 
systemic chemotherapy, could be regarded as independent prognostic factors for DMM patients. Otherwise, the 
change in serum CA125 can predict OS and response to systemic chemotherapy.
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Background
Malignant mesothelioma (MM) is a rare and fatal mes-
enchymal neoplasm arising from the serosal cavities 
(Kebapci et  al. 2003), commonly in pleura and perito-
neum, with a natural median survival of 6 months (Ruffie 
1991; de Pangher Manzini et  al. 1993). Treatment strat-
egy for MM including palliative cytoreductive surgery 
(CRS), systemic chemotherapy and intrapeural or intra-
peritoneal chemotherapy does not obtain satisfactory 
results (Nonaka et  al. 2005; Hadi et  al. 2006; Herndon 
et  al. 1998; Vogelzang et  al. 2003; Mineo and Ambrogi 
2012), with the median survival of less than 12  months 
(Creaney et al. 2013; Robinson and Lake 2005; Robinson 
et  al. 2003; Zucali et  al. 2011). Published paper demon-
strated that cytoreductive surgery and hyperthermic 
intraperitoneal chemotherapy (CRS/HIPEC) is a poten-
tially curative treatment for malignant peritoneal meso-
thelioma (MPeM) (Alexander et al. 2013).But because of 
the difficulty in early diagnosing, most patients are ini-
tially diagnosed in advanced stage that is not candidate 
for curative surgery (Grigoriu et al. 2007; Kao et al. 2011).
The serological biomarkers for response assess-
ment and prognosis of diffuse malignant mesothelioma 
(DMM) are very useful and important for therapeu-
tic decision-making. However, there is still no accepted 
tumor marker in routine clinical practice. Previous stud-
ies demonstrated that soluble mesothelin, with a sensitiv-
ity of 50 % and a specificity of 95 % (Robinson et al. 2003; 
Creaney et  al. 2007), could be a relevant tumor marker 
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and the baseline serum level of mesothelin is an inde-
pendent predictor of overall survival (Hollevoet et  al. 
2011; Linch et al. 2014). But few Chinese medical insti-
tutions had carried out mesothelin concentration. In 
clinical practice, we found that patients with DMM usu-
ally have elevated level of serum CA125. Furthermore, 
the elevated level of serum CA125 would decline when 
patients received systemic chemotherapy. Recent studies 
demonstrated mesothelin-CA125 binding is high affin-
ity and co-expressed in mesothelioma (Rump et al. 2004; 
Gubbels et al. 2006; Kaneko et al. 2009). These evidence 
suggested elevated levels of serum CA125 might be sen-
sitive for predicting disease progression (Kebapci et  al. 
2003; Hedman et  al. 2003; Baratti et  al. 2009), implying 
serum CA125 could be a potential prognostic marker. 
Similarly, there is no certain tumor marker for efficacy of 
systemic chemotherapy in DMM patients.
CA125 is a high molecular weight transmembrane 
glycoprotein well known as an independent predictor 
of progression-free survival (PFS) and overall survival 
(OS) in epithelial ovarian cancer (Chen et al. 2013). Fur-
thermore, CA125 test is a regular and convenient tumor 
marker in clinical practice in China.
This retrospective study aimed to evaluate the prog-
nostic and predictive value of the baseline levels of serum 




We identified patients attending Cancer Center of West 
China Hospital from April 2008 to April 2014 with a 
histologically or cytologically confirmed diagnosis of 
MM. All included patients were at stage III or IV that 
were unsuitable to curative surgery (Edge et  al. 2010; 
Troshichev et  al. 1988). The eligibility criteria included 
that age ≥18 years; Eastern Cooperative Oncology Group 
(ECOG) performance status was ≤2; histologically or 
cytologically confirmed diagnosis of MM and immuno-
histochemical tests excluded the possibilities of others 
metastatic carcinomas; must test at least the baseline 
level of serum CA125 before treatment and had follow-
up data in detail. Patients with history of other concomi-
tant neoplasm and chronic organ disorders that may 
affect the levels of serum CA125 were excluded. This 
study was approved by the Medical Ethical Committee 
of West China Hospital of Sichuan University (Chengdu, 
China) and written informed consent for data collection 
has been obtained.
In subgroup analysis to evaluate the change in serum 
CA125 as the indicator for the efficacy of systemic chem-
otherapy, we selected candidates from overall patients by 
following inclusive criteria: received at least one cycle of 
systemic chemotherapy; monitored the levels of serum 
CA125 at least every one or two cycles of chemother-
apy and had corresponding efficacy evaluated by CT or 
MRI according to Response Evaluation Criteria in Solid 
Tumors (modified RECIST) criteria.
CA125 assay
CA125 (U/ml) levels were measured in serum using the 
CanAg CA125 assay (Roche Diagnostics). Assays were 
run according to manufacturer’s instructions. The upper 
limit of normal range was 35 U/ml.
Treatment plan
All treatment strategies were selected by treating phy-
sician based on the patients’ physical and disease 
condition. The most common regimen of systemic 
chemotherapy was pemetrexed 500  mg/m2 and cispl-
atin 75  mg/m2 administered intravenously once every 
21 days. Local chemotherapy was mostly administered as 
cisplatin 30–40 mg/m2 once every 21 days.
Data collection
Data on age, gender, primary tumor location, histological 
subtype, stage of disease, ECOG performance status, sur-
gery, systemic chemotherapy, local chemotherapy, levels 
of serum CA125, efficacy assessment and survival infor-
mation were collected.
Normal range of serum CA125 in our hospital was 
0–35 U/ml. In chemotherapy subgroup, change in serum 
CA125 was defined as level of serum CA125 after treat-
ment minus the baseline level of serum CA125. Modified 
RECIST (Byrne and Nowak 2004) was used to evaluate 
the efficacy of systemic chemotherapy. OS was calculated 
from the date of advanced disease diagnosis until the 
death or the last recorded date of follow-up.
Statistical analysis
Kaplan–Meier methods were used to conduct the best 
stratified level of baseline serum CA125 associated with OS 
and the univariate analysis of potential prognostic factors. 
In multivariate analysis, Cox’s proportional hazards regres-
sion model was used to find the independent prognostic 
predictors for patients with DMM. Wilcoxon signed-rank 
test and Spearman rank correlation were used to conduct 
the association between the changes in serum CA125 and 
modified RECIST assessment. A value of P  <  0.05 were 
considered as statistically significant difference. The SPSS 
statistical software (IBM, V19) was used for all analyses.
Results
Patient characteristics
A total of 41 patients with DMM were included with a 
median age of 53  years (range from 24 to 80) and male 
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preponderance (ratio: 2.15 to 1). The patient character-
istics were shown in Table 1. Fourteen patients (34.2 %) 
had pathological epithelioid tumors subtype and most 
patients (31 patients, 75.6  %) were at stage IV. More 
than half of patients (23 patients, 56.1  %) had received 
systemic chemotherapy, whereas only 26.8 % of patients 
had undergone palliative CRS. The mean baseline serum 
CA125 was 351.3/ml (range 8.76–2017  U/ml), with the 
values of 31 patients (75.6 %) were >35 U/ml.
Twenty-three diffuse malignant pleural mesothe-
lioma (DMPlM) patients and 18 diffuse malignant peri-
toneal mesothelioma (DMPeM) patients were included 
in study. In DMPeM subgroup, 8 patients underwent 
palliative CRS while only 3 patients received palliative 
cytoreduction in DMPlM subgroup. There were thirty 
DMM patients without any palliative surgery in our 
study.
Overall survival
Median OS for all 41 patients was 10  months (range 
1–48  months, 95  % CI 4.633–15.367, Fig.  1). OS rates 
at 6, 12 and 18 months was 62.4 %, 44.6 %, and 41.4 %, 
respectively. Eighteen patients were alive when the study 
finished with a median follow-up of 30  months (range 
2–61 months). Survival results for DMPlM patients and 
DMPeM patients were presented in Fig. 2. 
Factors associated with OS in univariate analysis
A Log-rank test was used to find out potential prognos-
tic factors associated with OS. The best stratified level 
of baseline serum CA125 (shown in Table  2) associ-
ated with OS was 280 U/ml in our study (eight times of 
upper normal limit, P = 0.045, Fig. 3). Ten factors were 
considered into univariate analysis including age, gen-
der, ECOG performance status, primary tumor location, 
pathological subtype, stage of disease, CRS, systemic 
chemotherapy, local chemotherapy and baseline level 
of serum CA125. The following factors correlated with 
a better outcome (shown in Table  3) included: 0–1 PS 
score (HR 3.013, 95 % CI 1.208–7.513, P = 0.018), tumor 
located in peritoneum (HR 0.236, 95  % CI 0.091–0.613, 
P = 0.003), epithelial subtype (HR 2.281, 95 % CI 1.261–
4.124, P =  0.006), disease at stage III (HR 11.495, 95  % 
CI 1.572–87.701, P  =  0.017), systemic chemotherapy 
(HR 0.340, 95 % CI 0.142–0.810, P = 0.015) and the base-
line level of serum CA125 ≤ 280 U/ml (HR 2.214, 95 % 
CI 1.080–5.091, P = 0.045). Age, gender, CRS and local 
chemotherapy were not significantly related with OS.
Table 1 Patient Characteristics
Parameters No. (%)
Total 41 100
Sex ratio (M:F) 28:13
Median age, years (range) 53 (24–80)
 ≤60 years 28 68.3
 >60 years 13 31.7
Primary tumor location
 Pleura 23 56.1
 Peritoneum 18 43.9
Histological subtype
 Epithelial 14 34.2
 Sarcomatoid 1 2.4
 Unspecified 26 63.4
Stage of disease
 III 10 24.4
 IV 31 75.6
Performance status (ECOG)
 0–1 33 80.5
 2 8 19.5
Surgery
 Cytoreductive surgery 11 26.8
 non‑cytoreductive surgery 30 73.2
Systemic chemotherapy
 Yes 23 56.1
 No 18 43.9
Median cycles of systemic chemotherapy (range) 4 (1–15)
Local chemotherapy
 Yes 13 31.7
 Intrapleural chemotherapy 5 38.5
 Intraperitoneal chemotherapy 8 61.5
 No 28 68.3
Median cycles of local treatment (range) 5 (3–7)
Baseline of serum CA125 (range) 351.3 (8.96–2017)
 ≤35 U/ml 10 24.4
 >35 U/ml 31 75.6
Fig. 1 Overall survival of all 41 patients. The median overall survival 
(OS) for 41 patients was 10 months
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Factors associated with OS in multivariate analysis
Six factors were included into multivariate analysis con-
ducted by a Cox proportional hazard model to identify 
the independent prognostic factors of OS. Four variables 
seemed to be the independent prognostic factors (shown 
in Table  4). Tumor located in peritoneum (HR 0.289, 
95 % CI 0.096–0.870, P = 0.027), disease at stage III (HR 
14.571, 95 % CI 1.825–116.326, P = 0.011), received sys-
temic chemotherapy (HR 0.298, 95  % CI 0.099–0.900, 
P = 0.032) and baseline level of serum CA125 ≤ 280 U/
ml (HR 3.412, 95  % CI 1.265–9.208, P  =  0.015) were 
positive independent prognostic factors in patients with 
DMM.
The correlation between CA125 change and OS or 
radiological objective response
According the rigorous including criteria, 12 patients had 
regularly surveilled serum CA125 during systemic chem-
otherapy and finished corresponding efficacy evaluation. 
Wilcoxon signed-rank test assessed the differences in 
serum CA125 levels across the corresponding evaluation 
time points and found it differed significantly. Spearman 
rank correlation demonstrated a significant association 
between the change in serum CA125 and the response to 
systemic chemotherapy according to modified RECIST 
criteria (rCA125 = 0.857, P < 0.001, shown in Table 5). 
The median OS for patients who received systemic 
chemotherapy was significant longer than OS of patients 
without systemic chemotherapy (median survival: 
43 months in chemotherapy group vs. 4 months in chem-
otherapy-naïve group, P  =  0.015). Similarly, the mean 
level of baseline serum CA125 in systemic chemotherapy 
subgroup was 303.8  U/ml (range 10.19–1918  U/ml), 
while after receiving systemic chemotherapy, the mean 
level of serum CA125 was significantly declined to 96 U/
ml (range 5–462.9  U/ml). Figure  4 demonstrated the 
association between change in serum CA125 and OS. 
The change was divided into three grades: a decrease 
>6  U/ml, a change less than 6  U/ml (stable) and an 
increase >6 U/ml (selected by Log-rank methods) and the 
decline in serum CA125 was associated with better OS in 
patients with systemic chemotherapy (P = 0.017).
Discussion
DMM is considered as a difficult disease condition 
to make a diagnosis and monitor disease progression 
Fig. 2 The survival of DMPlM patients and DMPeM patients sub‑
groups. The median survival (OS) of DMPlM patients was 6 months. 
The median OS of DMPeM patients subgroup was longer than 
24 months, P = 0.003
Table 2 Different stratified levels of baseline serum CA125 
associated with overall survival in 41 patients
Normal range of serum CA125 in our hospital was 0–35 U/ml
a The quartile of baseline serum CA125 in study was 42.61, 138.60, 489.90 U/ml, 
respectively
Baseline of serum CA125 (U/ml) χ2 P
≤35 versus >35 2.501 0.114
≤42.61 versus >42.61a 2.924 0.087
≤70 versus>70 1.715 0.190
≤138.60 versus >138.60a 2.339 0.126
≤140 versus >140 2.339 0.126
≤210 versus >210 1.461 0.227
≤280 versus >280 4.001 0.045
≤350 versus >350 2.227 0.136
≤489.90 versus >489.90a 1.352 0.245
Fig. 3 The best stratified level of baseline serum CA125 for predict 
DMM patients outcome. The best stratified level of baseline serum 
CA125 for predict DMM patients outcome was 280 U/ml (eight times 
of upper normal limit), P = 0.045
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because of its unspecific clinical signs and lack of effec-
tive tumor-related markers. Level of serum CA125 was 
elevated in DMM patients and it co-expressed with mes-
othelin which was regarded as an independent prognos-
tic factor (Hollevoet et  al. 2011; Linch et  al. 2014). This 
retrospective study aimed to gain insight in the role of 
serum CA125 as biomarkers of response and outcome in 
patients with DMM.
In our study, we found the baseline level of serum 
CA125 might be considered as an independent prognos-
tic factor for patients with DMM. The serum CA125 has 
been shown to distinguish malignant from benign, moni-
tor therapeutic response and prognoses the OS for pelvic 
and ovarian cancer (Chen et al. 2013; Meyer and Rustin 
2000). And its researches for malignant mesothelioma 
have been reported. Hedman et al. (2003) found that the 
level of serum CA125 increased as mesothelioma pro-
gressed in 5 patients, while 3 patients had a stable disease 
with a decrease in level of CA125. Kebapci et al. (2003) 
found the mean baseline serum CA125 level of 11 malig-
nant peritoneal mesothelioma (MPeM) patients was 
230 U/ml. Baratti et al. (2007, 2009) reported that in non-
preoperative systemic chemotherapy subgroup, diffuse 
malignant peritoneal mesothelioma (DMPeM) patients 
with baseline CA125 ≤ 35 U/ml correlated to better OS 
compared with patients that baseline CA125 > 35 U/ml 
but failed to show the association between baseline levels 
of CA125 and OS in entire DMPeM patients. Our study 
Table 3 Prognostic significance of clinicopatholgic variables based on univariate analysis
–, did not reach the median OS
No. Median OS (months) Survival at months (%) Hazard ratio P value
6 12 18 24
Age 1.881 0.147
 ≤60 years 28 13 ± 10.2 74.6 52.4 47.6 47.6
 >60 years 13 5 ± 2.2 34.6 26.0 26.0 26.0
Gender 1.850 0.157
 Male 28 43 ± 25.1 67.9 52.4 52.4 52.4
 Female 13 6 ± 2.8 45.1 22.6 11.3 11.3
Performance status (ECOG) 3.013 0.018
 0–1 33 13 ± 15.4 68.3 53.0 48.9 48.9
 2 8 2 ± 1.4 37.5 12.5 12.5 12.5
Primary tumor location 0.236 0.003
 Pleura 23 6 ± 2.1 51.5 22.9 22.9 22.9
 Pritoneum 18 – 88.9 68.8 61.9 61.9
Histological subtype 2.281 0.006
 Epithelial 14 43 ± 27.9 85.7 85.7 85.7 85.7
 Sarcomatoid 1 13 1 1 0 0
 Unspecified 26 6 ± 1.5 56.7 20.4 20.4 20.4
Surgery 0.363 0.069
 CRS 11 – 90.0 70.0 60.0 60.0
 nCRS 30 7 ± 2.0 52.1 35.8 35.8 35.8
Systemic chemotherapy 0.340 0.015
 Yes 23 43 ± 31.8 77.1 60.9 55.4 55.4
 No 18 4 ± 3.0 43.8 25.0 25.0 25.0
Local chemotherapy 0.486 0.156
 Yes 13 – 61.5 61.5 61.5 61.5
 No 28 9 ± 2.1 61.6 37.3 32.0 32.0
Stage of disease 11.495 0.017
 III 10 – 88.9 88.9 88.9 88.9
 IV 31 7 ± 2.5 52.1 31.0 26.6 26.6
Baseline of CA125 2.214 0.045
 ≤280 U/ml 28 43 ± 23.4 70.6 57.7 52.9 52.9
 >280 U/ml 13 5 ± 1.7 44.9 17.9 17.9 17.9
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demonstrated patients with baseline CA125 > 280 U/ml 
(eight time of upper normal limit) had worse OS com-
pared with the patients that baseline CA125 ≤ 280 U/ml 
in overall DMM patients.
Baseline level of serum CA125  ≤  280  U/ml was also 
one of the independent prognostic factors for OS in mul-
tivariate analysis. Meanwhile, primary tumor location, 
stage of disease and systemic chemotherapy were the 
independent prognostic markers for DMM patients in 
our study and these factors have been confirmed in sev-
eral papers (Vogelzang et al. 2003; Hollevoet et al. 2011; 
van der Bij et  al. 2012; Tabata et  al. 2013), supporting 
their close association with prognosis.
In systemic chemotherapy subgroup, the radiological 
responses according to modified RECIST criteria were 
significantly associated with relative changes in serum 
CA125 levels. The level of serum CA125 significantly 
decreased after receiving systemic chemotherapy and 
this tendency was accompanied with the disease control 
rate. Furthermore, our study demonstrated the change 
in serum CA125 could be a prognostic factor of OS for 
DMM patients who had received systemic chemotherapy. 
There are no previous reports focusing on this aspect.
The test of serum CA125 concentration is cheaper and 
more convenient adjunct to monitor patient response 
and prognosis than CT or MRI which are recommended 
for response evaluation and follow-up (Meyer and Rus-
tin 2000; Stahel et al. 2009). Modified RECIST standard 
assessment is not adequate for DMM because DMM 
often present as a rind around the organs and pleu-
ral or peritoneal fluid rather than a spherical mass (van 
Klaveren et  al. 2004), so we think serum CA125, like 
CT or MRI recommended by ESMO and NCCN guid-
ance, should be included into regular tests to monitor the 
change of disease and predict the prognosis for DMM 
patients.
Our study had some limitations. It should be pointed 
out that our study was retrospective research with a small 
Table 4 Prognostic significance of clinicopatholgic variables based on multivariate analysis
Parameters Hazard ratio 95 % CI P value
Lower Upper
Tumor location (pleura vs. peritoneum) 0.289 0.096 0.870 0.027
Stage of disease (III vs. IV) 14.571 1.825 116.326 0.011
Systemic chemotherapy (no vs. yes) 0.298 0.099 0.900 0.032
Baseline level of serum CA125 (≤280 vs. >280 U/ml) 3.412 1.265 9.208 0.015
Table 5 Correlation between  the change in  serum CA125 
and the objective response
Systemic CT: systemic chemotherapy








1 10.19 12.74 2.55 SD
2 15.10 8.62 −6.48 SD
3 17.07 42.34 25.27 PD
4 30.67 5.00 −25.67 PR
5 53.52 58.67 5.15 PD
6 75.14 16.45 −58.69 SD
7 75.94 136.90 60.96 SD
8 138.60 10.11 −128.49 SD
9 176.20 161.90 −14.30 SD
10 519.40 229.90 −289.50 SD
11 615.90 6.70 −609.20 PR
12 1918.00 462.90 −1455.10 PR
Fig. 4 The association between change in serum CA125 and OS for 
patients who had received systemic chemotherapy
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sample size. Some patients do not had specific patho-
logical subtype may affect its role in prognosis. However, 
to our knowledge, our study is the first report to sys-
tematic analyzes the value of serum CA125 as a marker 
of response to therapy and prognosis in patients with 
DMM. Further validation of our findings is consequently 
required to elucidate the clinical value of CA125 in multi-
center, larger samples prospective studies. We believe our 
results could provide some important information for 
clinical practice.
Conclusions
In conclusion, the current study identify the best strati-
fied level of baseline serum CA125 associated with OS 
was 280 U/ml. Baseline level of serum CA125, accompa-
nied with stage of disease, primary tumor location and 
systemic chemotherapy, is an independent prognostic 
factor of DMM patients. For patients who receiving sys-
temic chemotherapy, the change in serum CA125 could 
reflect the efficacy of systemic chemotherapy in keeping 
with modified RECIST criteria and predict OS.
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